Efficacy and safety of everolimus-eluting stent (Xience Prime) in long coronary lesions

Trial Profile

Efficacy and safety of everolimus-eluting stent (Xience Prime) in long coronary lesions

Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 20 Oct 2015

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Therapeutic Use
  • Acronyms LONGPRIME
  • Most Recent Events

    • 20 Oct 2015 New trial record
    • 02 Sep 2015 Results presented at ESC Congress 2015: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top